TARA-002:
Cell-Based Therapy for Bladder Cancer MoA

TARA-002:
Cell-Based Therapy for Bladder Cancer MoA

TARA-002:
Cell-Based Therapy for Bladder Cancer MoA

TARA-002:
Cell-Based Therapy for Bladder Cancer MoA

Client:

Protara Therapeutics is a biotechnology company focused on developing therapies for cancer and rare diseases. Its lead candidate, TARA-002, is a cell-based therapy for non–muscle-invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) and has shown promising clinical trial results. Protara approached our team to create an animation that would clearly communicate the science behind TARA-002, illustrating its mechanism of action and potential benefits for healthcare professionals and patients.

Protara Therapeutics is a biotechnology company focused on developing therapies for cancer and rare diseases. Its lead candidate, TARA-002, is a cell-based therapy for non–muscle-invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) and has shown promising clinical trial results. Protara approached our team to create an animation that would clearly communicate the science behind TARA-002, illustrating its mechanism of action and potential benefits for healthcare professionals and patients.

Protara Therapeutics is a biotechnology company focused on developing therapies for cancer and rare diseases. Its lead candidate, TARA-002, is a cell-based therapy for non–muscle-invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) and has shown promising clinical trial results. Protara approached our team to create an animation that would clearly communicate the science behind TARA-002, illustrating its mechanism of action and potential benefits for healthcare professionals and patients.

Protara Therapeutics is a biotechnology company focused on developing therapies for cancer and rare diseases. Its lead candidate, TARA-002, is a cell-based therapy for non–muscle-invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) and has shown promising clinical trial results. Protara approached our team to create an animation that would clearly communicate the science behind TARA-002, illustrating its mechanism of action and potential benefits for healthcare professionals and patients.

Client:

Project Goal

Project Goal

Project Goal

Project Goal

Protara required a 90-second mechanism-of-action (MoA) animation as part of its corporate communications strategy. The animation needed to effectively convey the mechanism of TARA-002 to investors, healthcare professionals, and other stakeholders while remaining scientifically accurate and visually engaging. It was intended to support Protara’s broader communication goals and enhance understanding of the therapy.

See full animation.

Protara required a 90-second mechanism-of-action (MoA) animation as part of its corporate communications strategy. The animation needed to effectively convey the mechanism of TARA-002 to investors, healthcare professionals, and other stakeholders while remaining scientifically accurate and visually engaging. It was intended to support Protara’s broader communication goals and enhance understanding of the therapy.

See full animation.

Protara required a 90-second mechanism-of-action (MoA) animation as part of its corporate communications strategy. The animation needed to effectively convey the mechanism of TARA-002 to investors, healthcare professionals, and other stakeholders while remaining scientifically accurate and visually engaging. It was intended to support Protara’s broader communication goals and enhance understanding of the therapy.

See full animation.

Protara required a 90-second mechanism-of-action (MoA) animation as part of its corporate communications strategy. The animation needed to effectively convey the mechanism of TARA-002 to investors, healthcare professionals, and other stakeholders while remaining scientifically accurate and visually engaging. It was intended to support Protara’s broader communication goals and enhance understanding of the therapy.

See full animation.

3D visualization of T cells and macrophages destroying cancer cells on the inner surface of the bladder
3D visualization of T cells and macrophages destroying cancer cells on the inner surface of the bladder
3D visualization of T cells and macrophages destroying cancer cells on the inner surface of the bladder
3D visualization of T cells and macrophages destroying cancer cells on the inner surface of the bladder

T-cells and macrophages targeting and destroying cancer cells

T-cells and macrophages targeting and destroying cancer cells

T-cells and macrophages targeting and destroying cancer cells

T-cells and macrophages targeting and destroying cancer cells

TARA-002 Being internalized by cell

TARA-002 Being internalized by cell

TARA-002 Being internalized by cell

TARA-002 Being internalized by cell

3D visualization of the TLR2 receptor embedded in the membrane
3D visualization of the TLR2 receptor embedded in the membrane
3D visualization of the TLR2 receptor embedded in the membrane
3D visualization of the TLR2 receptor embedded in the membrane

TLR2 Receptor

TLR2 Receptor

TLR2 Receptor

TLR2 Receptor

"We had a great experience working with the team, who were knowledgeable and professional. We are very pleased with the quality of our medical animation."

"We had a great experience working with the team, who were knowledgeable and professional. We are very pleased with the quality of our medical animation."

"We had a great experience working with the team, who were knowledgeable and professional. We are very pleased with the quality of our medical animation."

"We had a great experience working with the team, who were knowledgeable and professional. We are very pleased with the quality of our medical animation."

Patrick Hsu
Patrick Hsu
Patrick Hsu

Senior Vice President, Investor Relations and
Corporate Affairs at Protara Therapeutics

Senior Vice President,
Investor Relations and
Corporate Affairs at
Protara Therapeutics

Close-up visualization of the dendritic cell interacting with the TARA-002 particles
Close-up visualization of the dendritic cell interacting with the TARA-002 particles
Close-up visualization of the dendritic cell interacting with the TARA-002 particles
Close-up visualization of the dendritic cell interacting with the TARA-002 particles

Dendritic cells stimulating the production of pro-inflammatory cytokines

Dendritic cells stimulating the production of pro-inflammatory cytokines

Dendritic cells stimulating the production of pro-inflammatory cytokines

Dendritic cells stimulating the production of pro-inflammatory cytokines

Schematic 3D visualization of the NMIBC tumor
Schematic 3D visualization of the NMIBC tumor
Schematic 3D visualization of the NMIBC tumor
Schematic 3D visualization of the NMIBC tumor

Non-muscle invasive bladder cancer

Non-muscle invasive bladder cancer

Non-muscle invasive bladder cancer

Non-muscle invasive bladder cancer

Streptococcus pyogenes transforming into TARA-002

Streptococcus pyogenes transforming into TARA-002

Streptococcus pyogenes transforming into TARA-002

Streptococcus pyogenes transforming into TARA-002

The Process

The Process

The Process

The Process

Animation type:

Animation type:

Animation type:

Animation type:

3D + High End 3D

3D + High End 3D

3D + High End 3D

3D + High End 3D

Project timline:

Project timline:

Project timline:

Project timline:

7 weeks

7 weeks

7 weeks

7 weeks

Review:

Review:

Review:

Review:

3 zoom calls + 7 e-mail feedback sessions

3 zoom calls + 7 e-mail feedback sessions

3 zoom calls + 7 e-mail feedback sessions

3 zoom calls + 7 e-mail feedback sessions

Team:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

Find out which of our 26 scientific animation options works best for investor relations and communications:

To accurately depict TARA-002’s effects, we balanced cellular- and molecular-level visualization while ensuring clarity in storytelling. Our goal was to simplify complex concepts, making the animation accessible to healthcare professionals, investors, and patients. By emphasizing visual storytelling, we translated intricate processes into an engaging, easy-to-follow narrative while maintaining scientific integrity throughout. This included highlighting cellular interactions, using anatomical references, enhancing immune cell visualizations, and blending molecular and cellular perspectives for clarity.


Anatomy Visualization:
To maintain spatial clarity, we incorporated a skeletal model as an anatomical reference, enabling seamless scene transitions and keeping the bladder’s location intuitive for the audience. This approach ensured the animation remained both scientifically accurate and easy to follow.


Enhanced Immune Cell and Molecular Animation:
We expanded our asset library to improve immune cell animations and illustrate how TARA-002 interacts with the immune system. Several scenes combined molecular cut-ins with cellular interactions to highlight key molecular events while maintaining a focus on cellular responses, resulting in a more dynamic and accurate representation of immune effects.


Optimization for Visual Clarity:
To support smooth storytelling and scientific accuracy, we made targeted adjustments to structural dimensions, particularly in scenes blending bacterial cell visuals with molecular interactions. These refinements helped maintain visual consistency and clarity throughout the animation.

To accurately depict TARA-002’s effects, we balanced cellular- and molecular-level visualization while ensuring clarity in storytelling. Our goal was to simplify complex concepts, making the animation accessible to healthcare professionals, investors, and patients. By emphasizing visual storytelling, we translated intricate processes into an engaging, easy-to-follow narrative while maintaining scientific integrity throughout. This included highlighting cellular interactions, using anatomical references, enhancing immune cell visualizations, and blending molecular and cellular perspectives for clarity.


Anatomy Visualization:
To maintain spatial clarity, we incorporated a skeletal model as an anatomical reference, enabling seamless scene transitions and keeping the bladder’s location intuitive for the audience. This approach ensured the animation remained both scientifically accurate and easy to follow.


Enhanced Immune Cell and Molecular Animation:
We expanded our asset library to improve immune cell animations and illustrate how TARA-002 interacts with the immune system. Several scenes combined molecular cut-ins with cellular interactions to highlight key molecular events while maintaining a focus on cellular responses, resulting in a more dynamic and accurate representation of immune effects.


Optimization for Visual Clarity:
To support smooth storytelling and scientific accuracy, we made targeted adjustments to structural dimensions, particularly in scenes blending bacterial cell visuals with molecular interactions. These refinements helped maintain visual consistency and clarity throughout the animation.

Why did we use this
animation type?

Why did we use this
animation type?

Why did we use this
animation type?

Why did we use this
animation type?

A main 3D animation style was chosen to balance cinematic aesthetics with scientific accuracy. By integrating cinematic storytelling techniques—such as strategic lighting, depth of field, and seamless transitions—we enhanced clarity while keeping the animation visually compelling. Focusing on cellular interactions allowed for a more intuitive understanding of TARA-002’s mechanism while maintaining scientific rigor.

A main 3D animation style was chosen to balance cinematic aesthetics with scientific accuracy. By integrating cinematic storytelling techniques—such as strategic lighting, depth of field, and seamless transitions—we enhanced clarity while keeping the animation visually compelling. Focusing on cellular interactions allowed for a more intuitive understanding of TARA-002’s mechanism while maintaining scientific rigor.

A main 3D animation style was chosen to balance cinematic aesthetics with scientific accuracy. By integrating cinematic storytelling techniques—such as strategic lighting, depth of field, and seamless transitions—we enhanced clarity while keeping the animation visually compelling. Focusing on cellular interactions allowed for a more intuitive understanding of TARA-002’s mechanism while maintaining scientific rigor.

A main 3D animation style was chosen to balance cinematic aesthetics with scientific accuracy. By integrating cinematic storytelling techniques—such as strategic lighting, depth of field, and seamless transitions—we enhanced clarity while keeping the animation visually compelling. Focusing on cellular interactions allowed for a more intuitive understanding of TARA-002’s mechanism while maintaining scientific rigor.

Outcome:

Outcome:

Outcome:

Outcome:

The final animation effectively conveyed TARA-002’s mechanism of action, striking a balance between scientific precision and accessibility. By integrating cinematic visuals with clear explanations, the animation became a powerful tool for investor relations, corporate presentations, and industry events. Completing the project within a fixed timeline ensured the animation was available for a key industry event, maximizing its impact across investor presentations and corporate communications. This project highlights how strategic animation techniques can enhance engagement and understanding in biotech communications, demonstrating the value of well-structured visual storytelling.

The final animation effectively conveyed TARA-002’s mechanism of action, striking a balance between scientific precision and accessibility. By integrating cinematic visuals with clear explanations, the animation became a powerful tool for investor relations, corporate presentations, and industry events. Completing the project within a fixed timeline ensured the animation was available for a key industry event, maximizing its impact across investor presentations and corporate communications. This project highlights how strategic animation techniques can enhance engagement and understanding in biotech communications, demonstrating the value of well-structured visual storytelling.

Full animation

Full animation

Full animation

Full animation

Contact us

Contact us

Contact us

Contact us

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor, New York, NY 10281, USA

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science is an award-winning medical animation and digital scientific communications company, trusted by leading biotech and pharmaceutical organizations since 2007, including J&J, Pfizer, Novartis, Roche, Takeda, Gilead, AbbVie, and 100+ others.

We specialize in science-grade MoA and MoD videos, medical animation, and scientific storytelling, as well as digital and AI-driven solutions for Medical Affairs, marketing, corporate communications, and investor relations.

Contacts

US toll-free

1 888 374-16-95

NY

1 516 340-37-30

London

44 20 3734-2517

Address

200 Vesey Street, 24th floor,
New York, NY 10281, USA

Social networks

LinkedIn Logo
Vimeo Logo

© 2026, Visual Science. All rights reserved.

Privacy policy & Cookie policy

Visual Science Logo
Visual Science Logo
Visual Science Logo